Neonatal anaesthesia dosing needs to be based on physiological characteristics of the
newborn, pharmacokinetic/pharmacodynamic considerations and the adverse effects profile …

Neonatal anaesthesia dosing needs to be based on physiological characteristics of the
newborn, pharmacokinetic knowledge, pharmacodynamic considerations and the adverse …

Abstract Anaesthesia dosing in infants (0–2 years) should be based on pharmacokinetic–
pharmacodynamic considerations and adverse effects profiles. Disease processes and …

Effective and safe drug administration in neonates should be based on integrated
knowledge on the evolving physiological characteristics of the infant who will receive the …

BACKGROUND:: Historically, the use of anesthetics and analgesics in neonates and infants
has been based on extrapolations from studies performed in adults and older children. Over …

Mechanistic models create a framework for the study of pharmacokinetic changes in infancy.
Understanding these changes allows a target concentration approach to therapy and …

The absorption, distribution, metabolism and excretion of drugs in a neonate differ markedly
from those of older children. The neonate undergoes rapid developmental change from …

Modelling and simulation continue to have an important role optimizing drug use during
anaesthesia. Models incorporating influential covariates that better describe drug …

The neonatal period represents a time of rapid growth and development. As a consequence,
significant pharmacokinetic changes occur. In addition, pharmacodynamic changes …

The neonatal period represents a time of rapid growth and development. As a consequence,
significant pharmacokinetic and pharmacodynamic changes occur. In addition, size, age …